Tenax Therapeutics

About Tenax Therapeutics

Tenax Therapeutics is focused on developing therapies for pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF), a debilitating and often fatal disease with no approved treatments. The company aims to address this unmet medical need through innovative drug development.

Products & Services

TNX-103:An oral formulation of levosimendan, a drug authorized in 60 countries in its intravenous form for acute decompensated heart failure (ADHF). The development program is derisked due to differentiated clinical data and an established safety profile.

Specialties

Pulmonary Hypertension (PH-HFpEF) Heart Failure Cardiovascular Disorders Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 100000000 MR: - FA: approximately $100 million FAN: 100000000	D: 2024-08-12 FD: 2024-08-12	9 investors
2	RT: Private Placement T: - FT: Private Placement	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2024-08-06 FD: 2024-08-06	-
3	RT: Public Offering T: - FT: Public Offering	A: 9040000 MR: - FA: approximately $9,040,000 FAN: 9040000	D: 2024-02-08 FD: 2024-02-08	-
4	RT: Public Offering T: - FT: Public Offering	A: 15600000 MR: - FA: approximately $15.6 million FAN: 15600000	D: 2023-02-03 FD: 2023-02-03	1 investors

Private Placement Latest

2024-08-12

$100.0M

9 investors (Pro only)

Private Placement 2024-08-06

$100.0M

Public Offering 2024-02-08

$9.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Chris Giordano

President and Chief Executive Officer

S

Stuart Rich

Chief Medical Officer

D

Doug Randall

Chief Business Officer

T

Thomas McGauley

Chief Financial Officer

D

Douglas Hay

EVP of Regulatory Affairs

G

Gillian Andor

Vice President of Clinical Operations

View 13 more team members with Pro

Unlock Full Team Directory

Recent News